Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Dose-Titration, Safety, Tolerability, and Pharmacokinetics Study Followed by an Open-Label Safety and Efficacy Evaluation of SRP-4045 in Advanced-Stage Patients With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Oct 2021
Price :
$35
*
At a glance
- Drugs Casimersen (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions; First in man
- Sponsors Sarepta Therapeutics
- 01 Sep 2021 Results published in the Muscle and Nerve
- 22 Nov 2018 Status changed from active, no longer recruiting to completed.
- 22 Aug 2017 Planned End Date changed from 1 Apr 2018 to 1 Mar 2020.